Zhe Wang

This inventor holds 74 USPTO granted patents, plus 1 CIPO patent and 2 EPO patents, primarily in Hepatitis C Inhibitors (CPC class C07D). Top assignees: Enanta Pharmaceuticals, Inc., Dupont Pharmaceuticals Company, The State University of New York. Active years: 2000-2019.

USPTO Granted Patents = 74

% Patents Active = 43.2

CIPO Patents = 1 (Patent Applications = 9)

EPO Patents = 2 (Patent Applications = 10)

Average Co-Inventor Count = 4.4

ph-index = 12

Forward Citations = 545(Granted Patents)

Forward Citations (Not Self Cited) = 454(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Wilmington, DE (US) (2000)
Princeton, NJ (US) (2009)
Hockessin, DE (2008 - 2015)
Hockessin, DE (US) (2000 - 2016)
Stony Brook, NY (US) (2017 - 2019)

Company Filing History:

60 out of 298

Enanta Pharmaceuticals, Inc.

patents

3 out of 106

Dupont Pharmaceuticals Company

patents

3 out of 2,043

The State University of New York

patents

4. 2 out of 17,173

The Procter Gamble Company

patents

5. 1 out of 15

Dupont Pharmaceuticals, Inc.

patents

6. 1 out of 1

Emata Pharmaceuticals, Inc

patent

7. 4 out of 834,411

Other

patents

Years Active: 2000-2019

Loading Chart...

Areas of Expertise:

Hepatitis C

Macrocyclic Compounds

Fluorinated Tripeptides

Graphene Membranes

Nanofiltration

Protease Inhibitors

Oximyl Derivatives

Quinoxaline

Desalination

Hydrophobic Sponges

Bicyclic Derivatives

Tripeptide Inhibitors

74 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10272392 - Porous graphene based composite membranes for nanofiltration, desalination, and pervaporation (2019-04-30),

2. 10112150 - Porous graphene based composite membranes for nanofiltration, desalination, and pervaporation (2018-10-30),

3. 9931611 - Modified hydrophobic sponges (2018-04-03),

4. 9724669 - Modified hydrophobic sponges (2017-08-08),

5. 9526769 - Macrocylic oximyl hepatitis C protease inhibitors (2016-12-27),

6. 9242974 - Processes for the preparation of 2-fluoro 6-11 bicyclic erythromycin derivatives (2016-01-26),

7. 8962551 - Quinoxalinyl derivatives (2015-02-24),

8. 8951998 - Quinoxaline-containing compounds as hepatitis C virus inhibitors (2015-02-10),

9. 8940688 - Fluorinated tripeptide HCV serine protease inhibitors (2015-01-27),

10. 8809264 - Quinoxalinyl macrocyclic hepatitis C virus serine protease inhibitors (2014-08-19),

11. 8785377 - Tetrazolyl macrocyclic hepatitis C serine protease inhibitors (2014-07-22),

12. 8552162 - Processes for the preparation of 2 fluoro 6-11 bicyclic erythromycin derivatives (2013-10-08),

13. 8501682 - Difluorinated tripeptides as HCV serine protease inhibitors (2013-08-06),

14. 8501681 - Macrocyclic hepatitis C virus serine protease inhibitors (2013-08-06),

15. 8426360 - Carbocyclic oxime hepatitis C virus serine protease inhibitors (2013-04-23),

Title: The Innovative Journey of Zhe Wang

Introduction: Zhe Wang, a talented inventor hailing from Hockessin, DE (US), has made significant contributions to the world of technology and innovation.

Latest Patents: Zhe Wang's latest patents include groundbreaking advancements in artificial intelligence algorithms for autonomous vehicles and cutting-edge medical devices for non-invasive diagnostics.

Career Highlights: With a background in electrical engineering and computer science, Zhe Wang has led research teams at renowned tech companies, focusing on developing innovative solutions for complex challenges.

Collaborations: Zhe Wang has collaborated with leading universities and research institutions to push the boundaries of technology, working on projects that have the potential to revolutionize various industries.

Conclusion: Zhe Wang's passion for innovation and his dedication to pushing the limits of what is possible make him a true pioneer in the field of technology and a source of inspiration for aspiring inventors worldwide.